Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA6 | P23280 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | CA3 | P07451 | 3/20 | 0.39 |
| ▸ | CA5A | P35218 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30050875 | 0.86 | OTC (0.41) | CA5BCA12CA6CA7CA9 | |
| SCHEMBL22596633 | 0.79 | DPP7 (0.42) | DPP7RRM1CASP2GNAI3GNAO1 | |
| SCHEMBL12556856 | 0.79 | DPP7 (0.36) | CA5BCA12CA6CA7CA9 | |
| SCHEMBL24779309 | 0.79 | CA5B (0.39) | CA5BCA12CA6CA7CA9 | |
| SCHEMBL16328894 | 0.78 | ECE1 (0.37) | CA5BCA12CA6CA7CA9 | |
| SCHEMBL22929127 | 0.78 | DPP7 (0.55) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL14003709 | 0.76 | CA5B (0.55) | CA5BCA12CA6CA7CA9 | |
| SCHEMBL16328504 | 0.76 | RRM1 (0.62) | DPP7RRM1CASP2GNAI3GNAO1 | |
| SCHEMBL17697634 | 0.75 | DPP7 (0.44) | CA5BCA12CA6CA7CA9 | |
| SCHEMBL20475924 | 0.75 | DPP7 (0.44) | CA5BCA12CA6CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132254-A1 | CATIONIC POLYMER AND USE FOR BIOMOLECULE DELIVERY | GENEDIT INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260071003-A1 | COMPOSITIONS AND METHODS FOR DIRECTING APOLIPOPROTEIN L1 TO INDUCE MAMMALIAN CELL DEATH | UNIV GEORGIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250387466-A1 | COMPOSITIONS OF NUCLEIC ACID NANOSTRUCTURES FOR VACCINES AND METHODS OF USE THEREOF | MASSACHUSETTS INST TECHNOLOGY (US) | 2025-12-25 | — | — | US | disclosed |
| US-12486318-B2 | Anti-guanosine antibody as a molecular delivery vehicle | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | disclosed |
| US-12344709-B2 | Cationic polymer and use for biomolecule delivery | GENEDIT INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20240400627-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND OTHER DISEASES HAVING UPREGULATED MTOR ACTIVITY | YALE UNIVERSITY | 2024-12-05 | — | — | US | disclosed |
| WO-2024178364-A1 | GENE THERAPY FOR TREATMENT OF PAIN | THE GENERAL HOSPITAL CORPORATION (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20230330219-A1 | NUCLEIC ACID NANOSTRUCTURE PLATFORM FOR PROGRAMMING IMMUNE STIMULATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-10-19 | — | — | US | disclosed |
| US-11590242-B2 | Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors | YALE UNIVERSITY (US) | 2023-02-28 | — | — | US | disclosed |
| EP-2981284-A1 | ANTI-TUMOR DNA VACCINE | Kyushu University National University Corporation (JP) | 2016-02-10 | — | — | EP | disclosed |
| WO-2014163213-A1 | ANTI-TUMOR DNA VACCINE | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387466-A1 | COMPOSITIONS OF NUCLEIC ACID NANOSTRUCTURES FOR VACCINES AND METHODS OF USE THEREOF | LGALS8, CD4, TLR8 | CA5B 3440/4885CA12 2713/4885CA6 2706/4885 |
| US-12486318-B2 | Anti-guanosine antibody as a molecular delivery vehicle | SSB, CHMP4B, LAMP2 | CA5B 2047/4885CA12 3418/4885CA6 2800/4885 |
| US-20240400627-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND OTHER DISEASES HAVING UPREGULATED MTOR ACTIVITY | PKD1, PKD2, PHAX | CA5B 4540/4885CA12 4640/4885CA6 4299/4885 |
| US-20260071003-A1 | COMPOSITIONS AND METHODS FOR DIRECTING APOLIPOPROTEIN L1 TO INDUCE MAMMALIAN CELL DEATH | APOL1, APOB, LY96 | CA5B 4529/4885CA12 3684/4885CA6 4348/4885 |
| US-20260132254-A1 | CATIONIC POLYMER AND USE FOR BIOMOLECULE DELIVERY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, BCL2A1, ANXA11 | CA5B 2923/4885CA12 380/4885CA6 570/4885 |
| US-12344709-B2 | Cationic polymer and use for biomolecule delivery | LNPEP, SLC67A1, PCBP1 | CA5B 3438/4885CA12 1267/4885CA6 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.